Ab0079 theaflavin Alleviates Collagen-Induced Arthritis in Mice by Decreasing Reactive Oxygen Species and Pro-Inflammatory Cytokines

Abstract

BackgroundAn autoimmune disease that causes inflammation and bone and cartilage deterioration is rheumatoid arthritis (RA). In the pathogenesis of RA, oxidative stress and pro-inflammatory cytokines are important factors. The main polyphenol in black tea, theaflavins (TFs), has been used medically to treat a variety of inflammatory illnesses by reducing inflammation and reactive oxygen species (ROS)ObjectivesThe medications available to treat RA have a variety of side effects. The current study was designed to assess the anti-arthritic properties of theaflavin in a mouse collagen-induced arthritis model.MethodsIn order to induce arthritis in DBA/1 mice, type II collagen was administered intradermally. From days 21 through days 42, different doses of theaflavin (50 and 100 mg/kg/day) were orally administered. To determine the effect of theaflavin on collagen-induced arthritis, histological analyses were conducted. In addition, the generation of reactive oxygen species (ROS), nitric oxide, and the activities of enzymatic antioxidants (superoxide dismutase, glutathione peroxidase, catalase, and glutathione reductase) in the joint homogenate of mice were examined. The levels of TNF-, IL-6, and IL-1β were also measured by ELISA to detect inflammation.ResultsOur results showed anti-oxidant and anti-inflammatory effects of theaflavin in arthritic mice. Histopathological studies corroborated the anti-arthritic properties of theaflavin. The compound was found to be effective in lowering ROS and nitric oxide levels while increasing enzymatic antioxidant levels. Theaflavin therapy also reduced TNF-, IL-6, and IL-1β levels.ConclusionIn mice with arthritis, theaflavin was successful in reducing inflammation and oxidative stress. These results suggest that theaflavin may be used in conjunction with other treatments to manage RA.Figure 1.TF ameliorated the severity of arthritis in CIA mouse models. (a) Representative photographs depicted the swollen and reddened rear paws of four animal groups 42 days following the initial vaccination. (b) Accumulated clinical arthritis scores in each leg ranged from 0 to 4 and were evaluated every three days using a visual scoring system. The changes in body weight of normal control or CIA mice treated with or without TF or vehicle were recorded every three days till day 42. (c) TNF-, IL-6, and IL-1 inflammatory cytokine protein levels in arthritic mouse hind paw tissues. On day 42, CIA in DBA/1 mice hind paw homogenates were taken from the normal control, vehicle-treated, or TF-treated (50 or 100 mg/kg) groups of mice. The cytokine profiles were measured using ELISA according to the techniques given. ** p < 0.01 and * p < 0.05 showed statistically significant differences in two-way ANOVA compared with the vehicle-treated CIA groupREFERENCES:NIL.Acknowledgements:NIL.Disclosure of InterestsNone Declared.